Company profile
Oxford Simcell
Oxford Simcell Limited is a UK company with status active founded in 2020 based in London.
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last accounts made up date
Last confirmation statement made up date
Company registered at Companies House
Oxford SimCell develops non-replicating synthetic bacterial cells for a variety of healthcare applications.
Oxford SimCell Ltd has been established as a spin-off company of Oxford University.
Oxford SimCell Ltd has already attracted £2M investment.
SimCells® are genome-free, non-replicating bacterial chassis produced by expressing a homing endonuclease within host cells, which enzymatically cleaves multiple restriction sites within the genome. This process completely halts cell division while preserving other key cellular features, making SimCells® useful for in vivo and in vitro applications that would be impossible with dividing cells. Manufacturing is a core competency at Oxford SimCell Ltd. Our production workflows let us provide pure, high-quality SimCells® engineered for broad applications across the healthcare sector. SimCell® technology was developed at the University of Oxford [1] and is exclusively licensed to Oxford SimCell Ltd.
1 Apr 2024 to 31 Mar 2025
Leveraging live bacteria for vaccines and therapies has long been an appealing concept, offering a comprehensive approach to targeting the immune system. However, the challenge lies in controlling this method, as it poses potential fatal consequences. Addressing this issue, SimCell technology, pioneered at the University of Oxford, presents a groundbreaki...
1 Feb 2024 to 31 Jan 2025
Using live bacteria as vaccines and therapies for diseases has long been seen as an attractive idea, offering a way to target the immune system more comprehensively. Unfortunately, the approach is difficult to control, with potentially dangerous side-effects. SimCell technology, developed at the University of Oxford, solves this problem by producing bacte...
1 Jan 2024 to 31 Mar 2026
Using live bacteria as vaccines and therapies for diseases has long been seen as an attractive idea, offering a way to target the immune system more comprehensively. Unfortunately, the approach is difficult to control, with potentially fatal consequences. SimCell technology, developed at the University of Oxford, solves this problem by producing live bact...
1 Jan 2024 to 31 Mar 2024
Using live bacteria as vaccines and therapies for diseases like cancer has long been seen as an attractive idea, offering a way to target the immune system more comprehensively. Unfortunately, the approach is difficult to control, with potentially fatal consequences. SimCell technology, developed at the University of Oxford, solves this problem by produci...
1 Sep 2023 to 31 Aug 2025
Using live bacteria as vaccines and therapies for diseases like cancer has long been seen as an attractive idea, offering a way to target the immune system more comprehensively. Unfortunately the approach is difficult to control, with potentially fatal consequences. SimCell technology, developed at the University of Oxford, solves this problem by producin...
1 Sep 2023 to 30 Nov 2024
Using live bacteria as vaccines and therapies for diseases has long been seen as an attractive idea, offering a way to target the immune system more comprehensively. Unfortunately, the approach is difficult to control, with potentially dangerous side-effects. SimCell technology, developed at the University of Oxford, solves this problem by producing bacte...
1 Jun 2023 to 30 Nov 2023
Using live bacteria as vaccines and therapies for diseases has long been seen as an attractive idea, offering a way to target the immune system more comprehensively. Unfortunately, the approach is difficult to control, with potentially fatal consequences. SimCell technology, developed at the University of Oxford, solves this problem by producing live bact...
